Next-Gen GLP-1 Race Intensifies as Novo Nordisk and Eli Lilly Patents Near Expiration

The Quick Take

• Pharmaceutical companies racing to develop next-generation GLP-1 weight-loss drugs with improved side effect profiles
• Key Novo Nordisk and Eli Lilly patents approaching expiration, intensifying competitive pressure across the sector
• Oral formulations and combination therapies currently in late-stage trials across multiple competing companies
• Window for branded incumbents to establish next-gen dominance before generic competition is narrowing rapidly

The GLP-1 receptor agonist market has emerged as the pharmaceutical sector's most contested battleground, driven by extraordinary commercial success of semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). Side effects including nausea, vomiting, and muscle loss have created a clinical gap that next-generation drugs aim to address. The race to improve tolerability while maintaining efficacy is attracting significant R&D investment from Pfizer, Amgen, Structure Therapeutics, and numerous biotechs. As foundational patents expire, the window for branded incumbents to establish next-generation dominance before generic competition is narrowing rapidly across the landscape.

Novo Nordisk (NVO) and Eli Lilly (LLY) stand most directly in the crosshairs of patent expiration risk, with their first-generation blockbusters generating combined revenues exceeding $30 billion annually. Winners in the next-generation race will likely be determined by clinical data quality, delivery innovation, and payer reimbursement dynamics. Amgen's MariTide, Pfizer's danuglipron, and Viking Therapeutics' VK2735 represent the leading challenger pipeline. The transition from injectable to oral formulations could dramatically expand the addressable patient population by reducing adherence barriers associated with weekly subcutaneous injections in the current standard-of-care.

Key forward signals include Phase 3 trial readouts expected from multiple programs through late 2026 and into 2027. FDA priority review designations for differentiated profiles could accelerate market entry for improved-tolerability candidates. Macro variables include healthcare policy decisions on GLP-1 drug coverage under Medicare and Medicaid, where reimbursement expansion would unlock significant volume growth. Investors should watch for partnership and licensing deals between larger pharmaceutical companies and smaller biotechs holding promising oral or differentiated GLP-1 assets, as deal activity tends to validate pipeline credibility and accelerate commercial timelines.

Synthesized from 1 source.